Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Antiviral Res. 2020 Aug 10;182:104904. doi: 10.1016/j.antiviral.2020.104904

Figure 6.

Figure 6.

Favipiravir (T-705) did not significantly improve survival in AG129 mice infected with a lethal challenge of LR06 CHIKV (A), while mice infected with S27 CHIKV were protected by various doses of T-705 (B) (**P<0.01, *P<0.05 as compared with placebo treatment).